Takeaways: The decision is especially meaningful for CELYSTRA because Québec is a high-prevalence region for FCS among French Canadians, so public coverage can quickly translate into concentrate...
Takeaways: Aspen-Semaglutide’s approval introduces the generic Ozempic-equivalent into Canada’s GLP‑1 space, setting up price competition and broader access in type 2 diabetes once API supply co...
Takeaways: Lilly now offers Canadian pediatric endocrinologists a once‑weekly injectable that addresses both glycemic control and weight – two core drivers of aggressiv...
The Obesity Drug Gold Rush: Healthcare Breakthrough or Market Frenzy? The global pharmaceutical industry is witnessing an unprecedented surge in demand for obesity therapies, transforming what was onc...
